TITLE

TrovaGene stops Sequenom, regains transrenal tech rights

PUB. DATE
August 2011
SOURCE
Medical Device Daily;8/11/2011, Vol. 15 Issue 150, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the termination of a license agreement between TrovaGene and Sequenom in 2011.
ACCESSION #
64371253

 

Related Articles

  • NUVELO ASSIGNS PATENTS TO SEQUENOM.  // Biotech Business;Nov2003, Vol. 16 Issue 11, p4 

    Reports on the patent assignment and license agreement signed by Nuvelo Inc. and SEQUENOM Inc. as of November 2003.

  • Sequenom signs European Licensing With LifeCodexx.  // Worldwide Biotech;Sep2011, Vol. 23 Issue 9, p3 

    The article reports on the licensing deal signed by biotechnology firms Sequenom Inc. and LifeCodexx AG for the commercialization of the European prenatal laboratory testing services. The deal will be Sequenom's first commercial partnership in the area of non-invasive prenatal diagnostics in...

  • Sequenom acquires rights to Optherion's AMD genetic tests.  // Medical Device Daily;2/10/2010, Vol. 14 Issue 27, p3 

    The article reports on the exclusive worldwide licensing agreement reached by Sequenom with Optherion in February 2010. It states that the deal will allow the Sequenom Center for Molecular Medicine the rights to manufacture and market diagnostic tests to predict genetic predisposition to late...

  • Skyline licenses TrovaGene's NMP1 technology for product.  // Medical Device Daily;6/23/2010, Vol. 14 Issue 120, p1 

    The article reports on the decision of Skyline Diagnostics to licensed its TrovaGene's NPM1 technology to be applied in one of its microarray equipment. According to Skyline, the equipment is planned to be used as a laboratory testing service in Europe and eventually outside Europe. Andreas...

  • Deals roundup.  // Medical Device Daily;9/23/2008, Vol. 12 Issue 203, p3 

    The article reports on the exclusive rights secured by Sequenom involving fundamental patent rights for digital polymerase chain reaction (PCR) technologies and methods under a licensing agreement with Genomic Nanosystems. The licensed rights include U.S. Patent Numbers 6,143,496 and 6,291,559...

  • Court report.  // Medical Device Daily;10/30/2009, Vol. 13 Issue 210, p6 

    The article reports that Xenomics complained Sequenom in the Supreme Court of the State of New York for fraudulent misrepresentation regarding the former's testing of the Down syndrome. It furthers that such conduct led to a license agreement of Xenomics with Sequenom with the former giving up...

  • Deals roundup.  // Medical Device Daily;10/31/2008, Vol. 12 Issue 213, p3 

    The article reports on the exclusive licensing agreement between Xenomics and Sequenom. Under the agreement, the latter will be given exclusive rights to use the patents of the former for the development of prenatal research and diagnostic products. Xenomics also has patents in other fields of...

  • TrovaGene Inc. Confirms It Has Regained Its Rights to Transrenal Technology for Non-Invasive Prenatal Testing and Cancer.  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p352 

    The article reports that TrovaGene Inc. has regained its rights to transrenal technology for non-invasive prenatal applications and cancer by terminating its license agreement with Sequenom Inc. Thomas Adams, TrovaGene's chairman, says that the recovery gives them the opportunity to expand their...

  • Sequenom to make offer for Exact, despite rejection.  // Diagnostics & Imaging Week;1/22/2009, Vol. 12 Issue 3, p2 

    The article highlights the intention of Sequenom to move forward with an exchange offer to acquire Exact Sciences in an all-stock transaction valued at $41 million, even though Exact reported earlier its board rejected an acquisition proposal by Sequenom. Under the proposed deal, each share of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics